JUN (Ab-63) Antibody

Shipped with Ice Packs
In Stock

Product Specs

Form
Supplied at 1.0mg/mL in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
Lead Time
Typically, we can ship the products within 1-3 business days after receiving your orders. Delivery times may vary depending on the purchase method or location. Please consult your local distributors for specific delivery time information.
Synonyms
Activator protein 1 antibody; AP 1 antibody; AP-1 antibody; AP1 antibody; cJun antibody; Enhancer Binding Protein AP1 antibody; Jun Activation Domain Binding Protein antibody; JUN antibody; Jun oncogene antibody; JUN protein antibody; Jun proto oncogene antibody; JUN_HUMAN antibody; JUNC antibody; Oncogene JUN antibody; p39 antibody; Proto oncogene c jun antibody; Proto oncogene cJun antibody; Proto-oncogene c-jun antibody; Transcription Factor AP 1 antibody; Transcription factor AP-1 antibody; Transcription Factor AP1 antibody; V jun avian sarcoma virus 17 oncogene homolog antibody; V jun sarcoma virus 17 oncogene homolog (avian) antibody; V jun sarcoma virus 17 oncogene homolog antibody; V-jun avian sarcoma virus 17 oncogene homolog antibody; vJun Avian Sarcoma Virus 17 Oncogene Homolog antibody
Target Names
JUN
Uniprot No.

Target Background

Function
JUN is a transcription factor that recognizes and binds to the enhancer heptamer motif 5'-TGA[CG]TCA-3'. It promotes the activity of NR5A1 when phosphorylated by HIPK3, leading to increased steroidogenic gene expression upon stimulation of the cAMP signaling pathway. JUN is also involved in activated KRAS-mediated transcriptional activation of USP28 in colorectal cancer (CRC) cells. It binds to the USP28 promoter in CRC cells.
Gene References Into Functions
  1. Research indicates that miR-139-5p is down-regulated in the hearts of Hypertrophic cardiomyopathy patients and that it inhibits cardiac hypertrophy by targeting c-Jun expression. PMID: 29440459
  2. This study identified a crucial Jun/miR-22/HuR regulatory axis in CRC (the working model is summarized in Fig. 8) and highlighted the vital role of HuR and miR-22 in CRC proliferation and migration. PMID: 29351796
  3. A novel cascade mediated by AP-1 and FOXF1 that regulates oncogene-induced senescence is reported. PMID: 30119690
  4. Multivalent Interactions with Fbw7 and Pin1 Facilitate Recognition of c-Jun by the Fbw7. PMID: 29225075
  5. High AP-1 expression is associated with metastasis in colon cancer. PMID: 29305742
  6. Our findings suggest that extended AP-1 binding sites, together with adjacent binding sites for additional TFs, encode part of the information that governs transcription factor binding sites activity in the genome. PMID: 29305491
  7. The expression of WIF-1 was low in GBC cells due to aberrant hypermethylation of its promoter region. Additionally, an alternative pathogenesis of GBC was indicated in which c-Jun causes hypermethylation of the WIF-1 promoter region, and represses the expression of WIF-1 through transcriptional regulation and interaction with DNMT1 as an early event in the tumorigenesis of GBC. PMID: 29693707
  8. Mutant cellular AP-1 proteins promote expression of a subset of Epstein-Barr virus late genes in the absence of lytic viral DNA replication. PMID: 30021895
  9. Secreted Ta9 has therefore, not only the ability to stimulate CD8+ T cells, but also the potential to activate AP-1-driven transcription and contribute to T. annulata-induced leukocyte transformation PMID: 29738531
  10. MiR-216b directly targets c-Jun, thereby reducing AP-1-dependent transcription and sensitizing cells to ER stress-dependent apoptosis. PMID: 27173017
  11. Results suggest that c-Jun, p38 MAPK, PIK3CA/Akt, and GSK3 signaling are involved in the effect of miR-203 on the proliferation of hepatocellular carcinoma cells. PMID: 28887744
  12. These findings suggest that increased JUN expression and activity may contribute to gefitinib resistance in non-small cell lung cancer. PMID: 28566434
  13. The results indicated that butein has antiproliferative and proapoptotic properties through the suppression of NF-kappaB, AP-1 and Akt signaling in HTLV-1-infected T cells, both in vitro and in vivo, suggesting its therapeutic potential against HTLV-1-associated diseases including adult T-cell leukemia/lymphoma PMID: 28586006
  14. Results show that VEGFA induces c-jun expression in mediating human retinal microvascular endothelial cell migration, sprouting and tube formation, and that Pyk2-STAT3 signaling enhances cJun expression in the mediation of retinal neovascularization. PMID: 27210483
  15. Increased c-jun expression is associated with nasopharyngeal carcinoma. PMID: 28269757
  16. Thrombin binding to PAR-1 receptor activated Gi-protein/c-Src/Pyk2/EGFR/PI3K/Akt/p42/p44 MAPK cascade, which in turn elicited AP-1 activation and ultimately evoked MMP-9 expression and cell migration in SK-N-SH cells. PMID: 27181591
  17. Findings provide evidence that phospho-c-Jun activates an important regulatory mechanism to control DNMT1 expression and regulate global DNA methylation in glioblastoma. PMID: 28036297
  18. Results demonstrated for the first time the regulatory mechanism of miR-744 transcription by c-Jun, providing a potential mechanism underlying the upregulation of miR-744 in cancers PMID: 27533465
  19. Results provide evidence that NuRD represses c-Jun transcription directly which, in the absence of MBD3, activates endogenous pluripotent genes and regulates induced cancer stem cells-related genes. PMID: 27894081
  20. Taken together, these results indicated that PAR1 signalingmediated cJun activation promotes early apoptosis of HUVEC cells induced by heat stress. PMID: 28447716
  21. Cheliensisin A (Chel A) treatment led to PH domain and Leucine rich repeat Protein Phosphatases (PHLPP2) protein degradation and subsequently increased in c-Jun phosphorylation, which could be attenuated by inhibition of autophagy mediated by Beclin 1. PMID: 27556506
  22. The positive feedback regulation of OCT4 and c-JUN, resulting in the continuous expression of oncogenes such as c-JUN, seems to play a critical role in the determination of the cell fate decision from induced pluripotent stem cells to cancer stem cells in liver cancer. PMID: 27341307
  23. miR-26b plays an anti-metastatic role and is downregulated in gastric cancer tissues via the KPNA2/c-jun pathway PMID: 27078844
  24. The IL1B/AP-1/miR-30a/ADAMTS-5 axis regulates cartilage matrix degradation in osteoarthritis. PMID: 27067395
  25. TGM2 is involved in amyloid-beta (1-42)-induced pro-inflammatory activation via AP1/JNK signaling pathways in cultured monocytes. PMID: 27864692
  26. Integrative genomic analysis indicated overexpression of the AP-1 transcriptional complex suggesting experimental therapeutic rationales, including blockade of the renin-angiotensin system. This led to the repurposing of the angiotensin II receptor antagonist, irbesartan, as an anticancer therapy, resulting in the patient experiencing a dramatic and durable response. PMID: 27022066
  27. Knockdown of CD44 reduced the protein level of xCT, a cystine transporter, and increased oxidative stress. However, an increase in GSH was also observed and was associated with enhanced chemoresistance in CD44-knockdown cells. Increased GSH was mediated by the Nrf2/AP-1-induced upregulation of GCLC, a subunit of the enzyme catalyzing GSH synthesis PMID: 28185919
  28. The study highlights the role of AP1 in promoting the host gene expression profile that defines Ebola virus pathogenesis. PMID: 28931675
  29. This is the first study to show how TGF-beta regulates the expression of Claudin-4 through c-Jun signaling and how this pathway contributes to the migratory and tumorigenic phenotype of lung tumor cells. PMID: 27424491
  30. Data show that BRD4 controls RUNX2 by binding to the enhancers (ENHs) and each RUNX2 ENH is potentially controlled by a distinct set of TFs and c-JUN as the principal pivot of this regulatory platform. PMID: 28981843
  31. AP-1 likely plays a more important role in the AR cistrome in fibroblasts. PMID: 27634452
  32. Elevated levels of bile acid increase the tumorigenic potential of pancreatic cancer cells by inducing FXR/FAK/c-Jun axis to upregulate MUC4 expression. PMID: 27185392
  33. Immunohistochemistry was employed to analyze cFos, cJun and CD147 expression in 41 UCB cases and 34 noncancerous human bladder tissues. PMID: 28358415
  34. Taken together, these findings indicate that LT reduces c-Jun protein levels via two distinct mechanisms, thereby inhibiting critical cell functions, including cellular proliferation. PMID: 28893904
  35. Expression of either dominant-negative or constitutively active mutants of Nrf2, ATF4, or c-Jun confirmed that distinct transcription units are regulated by these transcription factors. PMID: 27278863
  36. Mutually exclusive transcriptional regulation by AP-1 (cjun/cfos) and non-canonical NF-kappaB (RelB/p52) downstream of MEK-ERK and NIK-IKK-alpha-NF-kappaB2 (p100) phosphorylation, respectively, was responsible for persistent Ccl20 expression in the colonic cells. PMID: 27590109
  37. Glucocorticoid receptor (GR) is recruited to activator protein-1 (AP-1) target genes in a DNA-binding-dependent manner. PMID: 28591827
  38. These results suggested that hyperphosphatemia in the patients with CKD suppresses bone resorption by inhibiting osteoclastogenesis, and this impairs the regulation of bone metabolism. PMID: 28939042
  39. These results suggest that Bacteroides fragilis enterotoxin induced accumulation of autophagosomes in endothelial cells, but activation of a signaling pathway involving JNK, AP-1, and CHOP may interfere with complete autophagy. PMID: 28694294
  40. Overall, our results suggest that miR-4632 plays an important role in regulating HPASMC proliferation and apoptosis by suppression of cJUN, providing a novel therapeutic miRNA candidate for the treatment of pulmonary vascular remodeling diseases. It also implies that serum miR-4632 has the potential to serve as a circulating biomarker for PAH diagnosis. PMID: 28701355
  41. Findings suggest that AP-1 factors are regulators of RNA polymerase III (Pol III)-driven 5S rRNA and U6 snRNA expression with a potential role in cell proliferation. PMID: 28488757
  42. Our results indicate that assessing AP1 and PEA3 transcription factor status might be a good indicator of OAC status. However, we could not detect any associations with disease stage or patient treatment regime. This suggests that the PEA3-AP1 regulatory module more likely contributes more generally to the cancer phenotype. In keeping with this observation, depletion of ETV1 and/or ETV4 causes an OAC cell growth defect PMID: 28859074
  43. shRNA-mediated inhibition of JUN decreases AML cell survival and propagation in vivo. These data uncover a previously unrecognized role of JUN as a regulator of the unfolded protein response PMID: 27840425
  44. These findings demonstrate an essential role for the ERK pathway together with c-JUN and c-FOS in the differentiation activity of LukS-PV. PMID: 27102414
  45. The present study defines the minimal TIM-3 promoter region and demonstrates its interaction with c-Jun during TIM-3 transcription in CD4(+) T cells. PMID: 27243212
  46. Taken together, our data demonstrate that JNK regulates triple-negative breast cancer (TNBC) tumorigenesis by promoting CSC phenotype through Notch1 signaling via activation of c-Jun and indicate that JNK/c-Jun/Notch1 signaling is a potential therapeutic target for TNBC PMID: 27941886
  47. Regulation of osteosarcoma cell lung metastasis by the c-Fos/AP-1 target FGFR1 PMID: 26387545
  48. c-jun promoted FOXK1-mediated proliferation and metastasis via orthotopic implantation. PMID: 27882939
  49. Data provide evidence that AP-1 is a key determinant of endocrine resistance of breast cancer cells by mediating a global shift in the estrogen receptor transcriptional program. PMID: 26965145
  50. Comparison of how AP-1 (Jun/Jun dimer) and Epstein-Barr virus Zta recognize methyl groups within their cognate response elements PMID: 28158710

Show More

Hide All

Database Links

HGNC: 6204

OMIM: 165160

KEGG: hsa:3725

STRING: 9606.ENSP00000360266

UniGene: Hs.696684

Protein Families
BZIP family, Jun subfamily
Subcellular Location
Nucleus.
Tissue Specificity
Expressed in the developing and adult prostate and prostate cancer cells.

Q&A

What is the c-Jun protein and what cellular functions does it regulate?

c-Jun is a protein encoded by the JUN gene, which is the putative transforming gene of avian sarcoma virus 17. It functions as a critical component of the AP-1 (Activator Protein-1) transcription factor complex that regulates gene expression by interacting directly with specific DNA sequences . The gene is intronless and mapped to chromosome 1p32-p31, a region frequently involved in both translocations and deletions in human malignancies .

At the molecular level, c-Jun participates in numerous cellular processes including:

  • Cell proliferation and differentiation

  • Apoptosis regulation

  • Stress response pathways

  • Inflammatory signaling

  • Oncogenic transformation

The protein's activity is primarily regulated through phosphorylation events at specific serine residues, particularly serine 63 and 73, which enhance its transcriptional activity in response to various stimuli.

What epitope does JUN (Ab-63) Antibody specifically recognize?

JUN (Ab-63) Antibody specifically recognizes the peptide sequence around amino acids 61-65 (L-T-S-P-D) derived from Human c-Jun . This region is particularly significant as it contains serine 63, a critical phosphorylation site that regulates c-Jun transcriptional activity. The antibody detects endogenous levels of total c-Jun protein, regardless of phosphorylation status at this site .

The antibody was generated by immunizing rabbits with a synthetic peptide corresponding to this region conjugated to KLH (Keyhole Limpet Hemocyanin) carrier protein. It was subsequently purified through affinity chromatography using epitope-specific peptide columns to ensure high specificity .

What applications has JUN (Ab-63) Antibody been validated for?

JUN (Ab-63) Antibody has been validated for multiple experimental applications:

ApplicationValidatedRecommended Dilution
Western Blot (WB)Yes1:500-1:1000
ELISAYes0.1-0.5 μg/ml
Immunofluorescence (IF)Yes1:50-1:200
Immunohistochemistry (IHC)Yes2-5 μg/ml
Immunocytochemistry (ICC)Yes5 μg/ml
Flow CytometryYes1-3 μg/1×10^6 cells

Validation data typically includes experiments with positive control samples such as human HeLa, K562, Jurkat, and U-87MG cell lysates for Western blot applications, and human renal cell carcinoma tissue for IHC applications .

What species reactivity has been confirmed for JUN (Ab-63) Antibody?

The JUN (Ab-63) Antibody has been confirmed to react with c-Jun protein from multiple species:

Cross-reactivity testing ensures that the antibody recognizes the conserved epitope region (L-T-S-P-D) across these species. This cross-species reactivity is particularly valuable for comparative studies examining c-Jun expression and function across different model organisms .

What are the optimal storage and handling conditions for JUN (Ab-63) Antibody?

For optimal performance and longevity, JUN (Ab-63) Antibody should be stored and handled according to these guidelines:

  • Long-term storage: -20°C (recommended)

  • Short-term use: 4°C

  • Formulation: Supplied at 1.0mg/mL in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol

  • Avoid: Repeated freeze/thaw cycles that can degrade antibody quality

  • Reconstitution: For lyophilized format, reconstitute with 0.2 ml distilled water to yield a concentration of 500 μg/ml

Proper storage is critical for maintaining antibody performance in experimental applications. Aliquoting the antibody before freezing can prevent degradation associated with freeze/thaw cycles.

How can researchers optimize Western blot protocols for JUN (Ab-63) Antibody?

For optimal Western blot results with JUN (Ab-63) Antibody, researchers should implement this methodological approach:

Sample Preparation:

  • Use 30 μg of protein per lane for cell lysates under reducing conditions

  • Include positive controls such as Hela, K562, Jurkat, or U-87MG cell lysates

Electrophoresis Conditions:

  • Use 5-20% SDS-PAGE gel

  • Run at 70V (stacking gel) followed by 90V (resolving gel) for 2-3 hours

Transfer Parameters:

  • Transfer to nitrocellulose membrane at 150 mA for 50-90 minutes

  • Verify transfer efficiency with reversible protein stain before blocking

Blocking and Antibody Incubation:

  • Block membrane with 5% non-fat milk in TBS for 1.5 hours at room temperature

  • Incubate with JUN (Ab-63) Antibody at 0.5 μg/mL (1:500-1:1000 dilution) overnight at 4°C

  • Wash with TBS-0.1% Tween 3 times, 5 minutes each

  • Probe with goat anti-rabbit IgG-HRP secondary antibody at 1:5000 dilution for 1.5 hours at room temperature

Detection:

  • Develop using enhanced chemiluminescence (ECL) detection system

  • Expected band size for c-Jun is approximately 36-39 kDa

Troubleshooting Tips:

  • If background is high, increase washing steps or decrease primary antibody concentration

  • If signal is weak, extend exposure time or increase antibody concentration

What are the best practices for using JUN (Ab-63) Antibody in immunohistochemistry applications?

For effective immunohistochemical detection of c-Jun using JUN (Ab-63) Antibody, follow these methodological guidelines:

Tissue Preparation:

  • Fix tissues in 10% neutral buffered formalin

  • Embed in paraffin and section at 4-6 μm thickness

  • Mount sections on positively charged slides

Antigen Retrieval:

  • Perform heat-mediated antigen retrieval in EDTA buffer (pH 8.0)

  • For enzyme antigen retrieval, use standard enzyme antigen retrieval reagent for 15 minutes

Staining Protocol:

  • Block endogenous peroxidase activity with hydrogen peroxide

  • Block non-specific binding with 10% goat serum

  • Incubate with JUN (Ab-63) Antibody at 2-5 μg/ml overnight at 4°C

  • For detection, use appropriate secondary antibody system such as Peroxidase Conjugated Goat Anti-rabbit IgG (incubate for 30 minutes at 37°C)

  • Develop with DAB chromogen and counterstain with hematoxylin

  • Mount with permanent mounting medium

Positive Control Tissues:

  • Human renal cell carcinoma tissue

  • Human renal pelvis squamous metaplasia tissue

Expected Results:

  • c-Jun primarily exhibits nuclear localization with occasionally cytoplasmic staining

  • Expression patterns vary by tissue type and pathological state

How can JUN (Ab-63) Antibody be used to study phosphorylation-dependent signaling pathways?

While JUN (Ab-63) Antibody recognizes total c-Jun protein regardless of phosphorylation status, it can be utilized in combination with phospho-specific antibodies to study signaling pathways:

Experimental Approach:

  • Parallel Immunoblotting: Run duplicate samples on separate gels, probing one with JUN (Ab-63) Antibody and the other with phospho-specific c-Jun (S63) antibody

  • Quantitative Analysis:

    • Normalize phospho-c-Jun signal to total c-Jun detected by JUN (Ab-63) Antibody

    • Calculate phosphorylation ratios under different experimental conditions

  • Pathway Stimulation Experiments:

    • Treat cells with pathway activators (e.g., TNF-α, UV radiation, growth factors)

    • Monitor changes in c-Jun phosphorylation relative to total protein levels

    • Combine with inhibitors to verify pathway specificity

  • Antibody Array Approach:

    • Implement antibody array systems for insulin signaling pathways

    • Include JUN (Ab-63) Antibody alongside phospho-specific antibodies

    • Analyze pathway activation profiles across different experimental conditions

  • Time-Course Studies:

    • Monitor both total and phosphorylated c-Jun levels over time following stimulus

    • Determine activation and deactivation kinetics of the signaling pathway

This methodology allows researchers to distinguish between changes in c-Jun expression versus changes in its phosphorylation state, providing insights into signaling dynamics.

How can researchers optimize immunofluorescence protocols with JUN (Ab-63) Antibody?

For high-quality immunofluorescence results with JUN (Ab-63) Antibody, implement this optimized protocol:

Cell Preparation:

  • Culture cells on glass coverslips or chamber slides

  • Fix using 4% paraformaldehyde and permeabilize with permeabilization buffer

Staining Protocol:

  • Block with 10% normal goat serum to reduce non-specific binding

  • Incubate with JUN (Ab-63) Antibody at 5 μg/mL dilution overnight at 4°C

  • For co-staining experiments, combine with other primary antibodies (e.g., anti-Beta Tubulin)

  • Use appropriate fluorescently conjugated secondary antibodies (e.g., DyLight®488 Conjugated Goat Anti-Rabbit IgG) at 1:100 dilution

  • Incubate for 30 minutes at 37°C

  • Counterstain nuclei with DAPI

  • Mount with anti-fade mounting medium

Controls:

  • Include negative controls (omitting primary antibody)

  • Use A431 cells as positive control

  • For validation, compare nuclear staining pattern with DAPI counterstain

Imaging Parameters:

  • Visualize using appropriate filter sets for the fluorophores used

  • Capture z-stack images to ensure complete signal detection

  • Compare c-Jun localization with other cellular markers

Optimization Tips:

  • Adjust antibody concentration based on signal-to-noise ratio

  • Optimize permeabilization conditions for nuclear antigen access

  • For weak signals, extend primary antibody incubation time

What considerations are important when using JUN (Ab-63) Antibody in flow cytometry applications?

For successful flow cytometry experiments with JUN (Ab-63) Antibody, researchers should follow these methodological guidelines:

Sample Preparation:

  • Fix cells with 4% paraformaldehyde

  • Permeabilize cells with appropriate permeabilization buffer to allow antibody access to intracellular antigens

  • Block with 10% normal goat serum to minimize non-specific binding

Staining Protocol:

  • Incubate with JUN (Ab-63) Antibody at 1-3 μg per 1×10^6 cells

  • Use appropriate fluorochrome-conjugated secondary antibody

  • Include proper compensation controls when performing multicolor analysis

Controls:

  • Use U20S cells as positive control

  • Include isotype control antibody (rabbit IgG) at equivalent concentration

  • Perform unstained and secondary-only controls

Analysis Considerations:

  • Gate on viable cell population

  • Analyze intracellular c-Jun expression using appropriate statistical methods

  • For multiparameter analysis, consider co-staining with markers of cell cycle or activation

Expected Results:

  • c-Jun expression may vary across cell cycle stages

  • Stimulus-induced changes in c-Jun expression can be quantitatively measured

  • Population heterogeneity can be assessed through histogram analysis

How can JUN (Ab-63) Antibody be integrated into multiplexed antibody arrays for signaling pathway analysis?

Researchers can effectively incorporate JUN (Ab-63) Antibody into multiplexed antibody arrays using these methodological approaches:

Array Construction:

  • Covalently immobilize JUN (Ab-63) Antibody alongside other signaling pathway antibodies on glass surfaces coated with polymeric 3D material

  • Include both total protein and phospho-specific antibodies for comprehensive pathway analysis

Sample Processing:

  • Label proteins in cell lysates with biotin

  • Capture targeted proteins with immobilized antibodies on the array

  • Detect with Cy3-labeled streptavidin or other fluorescent detection systems

Analytical Approaches:

  • Compare relative signal intensities across different experimental conditions

  • Normalize target protein signals to appropriate housekeeping proteins

  • Perform cluster analysis to identify coordinated signaling responses

Validation Methods:

  • Confirm key findings using conventional Western blot

  • Validate with multiplexed bead array assays for orthogonal confirmation

  • Perform follow-up functional studies on identified pathway components

Application Areas:

  • Analyze insulin signaling pathway defects

  • Investigate c-Jun's role in stress-activated protein kinase cascades

  • Study oncogenic signaling networks in cancer models

This approach enables comprehensive analysis of c-Jun's involvement in complex signaling networks and provides a versatile method for detecting both total protein levels and post-translational modifications in normal and pathological states .

Quick Inquiry

Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *
© Copyright 2025 TheBiotek. All Rights Reserved.